{
  "figure_1": "Study flow diagram.",
  "figure_2": "Methodological quality summary: review authors' judgements about each methodological quality item for each included study.",
  "figure_3": "Network structure for efficacy outcomes at 1 year",
  "figure_4": "All direct and mixed comparisons: gain of 3 or more lines of visual acuity at 1 year",
  "figure_5": "All direct and mixed comparisons: mean change in visual acuity at 1 year",
  "figure_6": "All direct and mixed comparisons: mean change in central retinal thickness at 1 year (micron)",
  "figure_7": "Contribution plot of mean overall study risk of bias to pairwise network estimates. Legends show the risk of bias of each direct comparison.",
  "figure_8": "Network structure for safety outcomes at 1 year",
  "figure_9": "All direct and mixed comparisons: arterial thromboembolic events at the longest available follow‐up (1 or 2 years)",
  "figure_10": "All direct and mixed comparisons: all‐cause death at the longest available follow‐up (1 or 2 years)",
  "figure_11": "Comparison‐adjusted funnel plot for all outcome measures",
  "figure_12": "Comparison 1 Ranibizumab versus laser photocoagulation at 6 to 12 months, Outcome 1 Quality of life: NEI‐VFQ composite score at 6 to 12 months."
}